Jeff Patton, MD, chief executive officer of Tennessee Oncology, discusses if there's concern over what comes when the Oncology Care Model (OCM) ends.
Jeff Patton, MD, chief executive officer of Tennessee Oncology, discusses if there's concern over what comes when the Oncology Care Model (OCM) ends.
Transcript
Is there concern or anticipation among providers about what might come after OCM ends?
I think less concern about what might come after OCM. It’s clear that we’re going in that direction with value, and so, we have confidence that OCM will be iterated and 2.0 will be better than 1.0 was. We have a fair amount of influence on that. I’m on the [Community Oncology Alliance] board, so I have a lot of input into the COA feedback. We also use Tuple Health as our consultants; they have the ears of CMS. I actually know, personally, the soon to be named director of CMMI, who is really smart and will give us a lot of confidence in building on the successes, and I think OCM has been a success. There are some flaws like any initial system, but we have confident that 2.0 will be better than 1.0.
What are your thoughts on COA's proposed OCM 2.0? Does it address concerns that providers have with the current model?
COA’s had a lot of input and a lot of help from Tuple and Kavita Patel, MD, to help address the flaws in the current model, but also it includes some things that should probably have been in the initial model. Again, a lot of confidence with what’s coming out of COA. I just hope we can get them to implement it.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More